Navigation Links
Synthetic biology -- opportunities and risks
Date:8/3/2009

The new research field of synthetic biology will, in the medium term, open up a great deal of potential for combining novel genetic methods with engineering principles. This will facilitate the development, not only of new vaccines and medicines, but also of fuels and new materials. Early-stage dialogue with the public on the natural science, legal, economic and ethical issues is crucial for the success and acceptance of this new technology. With a joint position paper on the opportunities and risks posed by synthetic biology, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), acatech (the German Academy of Science and Engineering), and the German Academy of Scientists Leopoldina, the National Academy of Sciences, now want to initiate this dialogue.

The new statement was presented today by the Presidents of the three organisations, Professors Matthias Kleiner (DFG), Reinhard Httl (acatech) and Volker ter Meulen (Leopoldina), at a press conference in Berlin.

In four chapters totalling 40 pages, the research policy paper takes a stance on selected research fields, current challenges, and the safety and ethical issues raised by the forward-looking research field of synthetic biology.

In synthetic biology, two research approaches predominate: on the one hand, inanimate substances are used to construct "the building blocks of life". These are then combined to form a living organism. On the other, researchers attempt to remove components from natural organisms and replace them with others in order to create artificial life forms. These methods are based on the advances in gene technology, in particular the technical feasibility of increasingly rapidly decoding genetic information and re-synthesising it. In the medium term, the potential applications of synthetic biology range from medicine and environmental technology right through to biotechnology.

A group of experts led by Berlin-based microbiologist Professor Brbel Friedrich, a member of the DFG Senate Commission on Genetic Research and Vice President of the Leopoldina, developed the joint statement based on the findings of an international and interdisciplinary workshop held in Berlin on 27 February. The workshop brought together scientists and academics from the fields of biochemistry, molecular biology, genetics, microbiology, virology, chemistry, physics and the engineering sciences, as well as from the humanities and social sciences.

The statement was subsequently passed by the Executive Committees of the three organisations and defines five spheres of activity to outline how Germany can best profit from the potential offered by synthetic biology. These five spheres of activity are:

  • the strengthening of basic research
  • the bundling of relevant disciplines in research and education
  • the development of patenting processes
  • the elimination of threats and the prevention of misuse
  • the monitoring of this new research field using technology assessment methods

For the foreseeable future, the focus of synthetic biology will, in the opinion of the three organisations, lie in basic research. The paper comes to the conclusion that the success of synthetic biology will depend substantially on the extent to which it is able to bring together the wide variety of disciplines as early as the student training stage. Safety-relevant aspects are also addressed, with the paper concluding that, according to the current state of research, the existing laws aimed at ensuring biological safety (biosafety) and at eliminating potential misuse (biosecurity) are sufficient. Despite this, a continuous discussion on safety-relevant issues is considered necessary. This should, in the authors' opinion, be assigned to the Central Commission for Biological Safety (ZKBS).

The "Synthetic Biology" statement is directed particularly at politicians and interested members of the public.


'/>"/>

Contact: Dr. Eva-Maria Streier
em.streier@dfg.de
49-228-885-2250
Deutsche Forschungsgemeinschaft
Source:Eurekalert

Related medicine news :

1. New Study Finds Yet Another Link to Cancer, Synthetic Hormones
2. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Organic Left Standing as the Gold Standard for Consumers Looking to Avoid Food Produced With Synthetic Growth Hormones
5. QLT announces completion of Phase Ia safety trial of its synthetic retinoid product
6. Synthetic gene circuit allows precise dosing of gene expression
7. CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization
8. Brookhaven Lab and BioSET patent a synthetic peptide that enhances bone growth
9. Synthetic HDL Could Fight Heart Disease
10. Synthetic HDL: A new weapon to fight cholesterol problems
11. New center launched today to spearhead UK research in synthetic biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Orbita’s Nathan ... Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: Technology ... Home Event hosted by Parks Associates, a market research and consulting firm specializing ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Patients in ... call Dr. Angela Cotey’s practice to schedule an appointment, with or without a referral. ... frequently offers pulpotomy treatments to pediatric patients as a healthy alternative to a tooth ...
(Date:5/22/2017)... ... 22, 2017 , ... Today, Our Urgent Care celebrates the grand opening of ... cutting ceremony. Since opening over a month ago, Our Urgent Care Washington has ... The new Our Urgent Care walk-in clinic is located at 3195 Phoenix Center Dr., ...
(Date:5/22/2017)... ... May 22, 2017 , ... Faithfully following pop culture, people today are ... toned and shaped through fitness programs. It carries on to skin nourished, pampered and ... an irresistible, radiant smile. CDA has found that just like a perfectly ...
(Date:5/21/2017)... , ... May 19, 2017 , ... ... to announce the appointment of James (Jim) Vertino as Chief Information Officer (CIO). ... proven, transformational leader who drives innovation and business performance. He defines strategic roadmaps ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology: